Advertisement
Home »

Addition of Pembrolizumab Improves pCR in Patients With Early-Stage High-Risk ER+/HER2- Breast Cancer

Oct 27, 2023

REFERENCES & ADDITIONAL READING

Torrisi R, et al. Crit Rev Oncol Hematol. 2021;160:103280.

 

Cortes J, et al. N Engl J Med 2022;387:217–226.

 

Cardoso F, et al. KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2-breast cancer. Abstract LBA21, ESMO 2023, 20–24 October, Madrid, Spain.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement